Clinical trial of 3-methyl-5-(beta-N'-(N-m-chlorophenylpiperazino)ethyl)-pyrazole dihydrochloride (Mepiprazol) in the therapy of psychovegetative disorders.
In a clinical trial of 30 patients suffering from psychovegetative disorders and anxiety neuroses, Mepiprazol (test designation: EMD 16-923; supplier: E. Merck, Darmstadt, FRG) was proven in a treatment period of 14 days to be an effective, well-tolerated medication. Only two patients failed to respond during the course of treatment. Improvements were significant at the 1-percent level between the pretreatment condition and each control during the treatment period; even between the rating times there was a significant increment in treatment success. Mepiprazol had a particular effect on symptoms such as irritability, anxiety, inner unrest and tension. Mepiprazol also exhibited a positive effect in the treatment of psychosomatic complaints.